Delayed Nasdaq 10:44:06 2024-04-19 am EDT 5-day change 1st Jan Change
1.405 USD -1.67% Intraday chart for Exagen Inc. -5.07% -29.40%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (XGN) EXAGEN Reports Q4 Revenue $13.8M, vs. Street Est of $11.6M MT
Transcript : Exagen Inc., Q4 2023 Earnings Call, Mar 18, 2024
Exagen Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 CI
Exagen Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Investors -2- DJ
Exagen Inc. Reaffirms Earnings Guidance for the Full Year Ended December 31, 2023 CI
Exagen Files $150 Million Mixed Shelf MT
Exagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Exagen Inc., Q3 2023 Earnings Call, Nov 13, 2023
Earnings Flash (XGN) EXAGEN Reports Q3 Revenue $13.4M, vs. Street Est of $10.3M MT
Exagen Reaches Settlement With US Department of Justice Over Alleged Kickbacks to Promote Lab Test Use MT
Exagen Reaches Settlement With US Department of Justice Over Alleged Kickbacks to Promote Lab Test Use MT
Exagen Agrees to Pay Over $650K to Resolve Kickback Allegations DJ
Transcript : Exagen Inc., Q2 2023 Earnings Call, Aug 07, 2023
Earnings Flash (XGN) EXAGEN Reports Q2 Revenue $14.1M, vs. Street Est of $10.9M MT
Exagen Inc. Provides Revenue Guidance for the Third Quarter of 2023 CI
Exagen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
North American Morning Briefing : Investors Await -2- DJ
Exagen Inc. Appoints Paul Kim as Class II Director CI
Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : Exagen Inc., Q1 2023 Earnings Call, May 15, 2023
Earnings Flash (XGN) EXAGEN Posts Q1 Revenue $11.2M, vs. Street Est of $9.4M MT
Exagen Inc. Provides Revenue Guidance for the Second Quarter of 2023 CI
Exagen Inc. Enters into the Third Amendment to Loan and Security Agreement CI
Chart Exagen Inc.
More charts
Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.429 USD
Average target price
5.5 USD
Spread / Average Target
+284.91%
Consensus
  1. Stock Market
  2. Equities
  3. XGN Stock
  4. News Exagen Inc.
  5. Exagen, Queen Mary University to Collaborate on Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection